Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

GlobeNewswire April 8, 2020

IIROC Trade Resumption - RVV

Canada NewsWire April 3, 2020

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

GlobeNewswire April 3, 2020

IIROC Trading Halt - RVV

Canada NewsWire April 3, 2020

Investor Announcement

GlobeNewswire April 3, 2020

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

GlobeNewswire March 30, 2020

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

GlobeNewswire March 25, 2020

IIROC Trade Resumption - RVV

Canada NewsWire March 24, 2020

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

GlobeNewswire March 24, 2020

IIROC Trading Halt - RVV

Canada NewsWire March 24, 2020

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

GlobeNewswire March 20, 2020

Revive Therapeutics Announces Closing of Brokered Private Placement

GlobeNewswire March 18, 2020

IIROC Trade Resumption - RVV

Canada NewsWire March 5, 2020

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

GlobeNewswire March 5, 2020

IIROC Trading Halt - RVV

Canada NewsWire March 5, 2020

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

GlobeNewswire February 18, 2020

IIROC Trade Resumption - RVV

Canada NewsWire February 12, 2020

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

GlobeNewswire February 12, 2020

IIROC Trading Halt - RVV

Canada NewsWire February 12, 2020

Revive Therapeutics Announces Brokered Private Placement of up to $2 million

GlobeNewswire February 11, 2020